Nasus Pharma (NSRX) Total Debt (2022 - 2025)
Nasus Pharma (NSRX) total debt from Dec 31, 2022 to Dec 31, 2025. The current Nasus Pharma (NSRX) total debt is $2.24M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Total Debt
Total Debt
Nasus Pharma (NSRX) Total Debt CAGR table
| Period | CAGR |
|---|---|
| 1 Year | -43.00% |
Annual Total Debt change of Nasus Pharma (NSRX)
| Year | Total Debt | Change |
|---|---|---|
| 2025 | $2.24M | -43.00% |
| 2024 | $3.93M | N/A |
| 2023 | $0 | N/A |
| 2022 | $0 | N/A |
Comparison Nasus Pharma (NSRX) total debt with competitors
Nasus Pharma (NSRX) total debt is $2.24M.
| Ticker | Name | Total Debt | Upside |
|---|---|---|---|
| MIRA | Mira Pharmaceuticals Inc | $114761.00 | -94.88% |
| MDCX | MDCorp | $6.00M | +167.81% |
| MDCXW | Medicus Pharma Ltd warrant | $6.00M | +167.81% |
| AMRN | Amarin Corp | $196.35M | +8665.67% |
| SCLX | Scilex Holding Company | $547.71M | +24351.12% |
| BIIB | Biogen Inc | $10.83B | +483444.64% |
| OGN | Organon & Company | $12.09B | +539766.07% |
| GRFS | Grifols SA | $12.24B | +546496.23% |
| SNY | Sanofi | $54.88B | +2449944.64% |
| GSK | GSK Plc | $59.93B | +2675389.24% |
| BMY | Bristol-Myers Squibb Company | $66.37B | +2963025.00% |
| AZN | Astrazeneca plc | $66.63B | +2974498.21% |
| NVS | Novartis AG | $79.61B | +3553694.64% |
| PFE | Pfizer Inc | $117.21B | +5232667.86% |
| JNJ | Johnson & Johnson | $119.71B | +5344007.14% |
| NVO | Novo Nordisk | $356.16B | +15899721.43% |